Gold prices reach record highs with projections of $3,700 by year-end.

Despite turmoil in the stock market, broad financial conditions in credit markets remain in la-la land, or are just barely exiting. It’s hard to keep the yield chasers down. Read more here..

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors. See why TEM stock is a Buy.

Mark Paris, Chief Investment Officer and Head of Municipal Strategies at Invesco US, explains potential outcomes of the municipal bond tax exemption debate and SALT deduction.

TransMedics faces stiff competition from advanced cold storage and NRP techniques. Read why I downgrade TMDX stock from hold to sell.

Eldorado Gold made another material upward revision in capex at Skouries. Check out Q4 and FY2024 results review, recent developments, and my rating for EGO stock.

Explore the hidden risks threatening your BDC income and find out which BDCs are still worth buying at High-Yield Investor. Read more here.

Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval. Read more to see a full investment analysis for IOVA stock.

DoJ says Google must be prevented from using AI to boost online search supremacy. China's Nio delays Europe launch of Firefly EV citing challenges. FDA suspends milk quality testing.

Brookfield Renewable's robust fundamentals include 10% FFO growth and strong corporate PPAs. Read why BEP stock is a Strong Buy.

Crescent Capital BDC has a 12.4% yield and Federal Realty has 57-year dividend streak. Read here for two top income investments this spring.

Amazon stock faces a 30% drop amid tariff fears and cost pressures, but high-margin segments like AWS and ads fuel growth. See more on AMZN stock here.

The ClearBridge International Value Strategy outperformed its MSCI EAFE benchmark during the first quarter of 2025. Click here to read the full commentary.

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I rate ORIC stock a hold.

HCA Healthcare, which is set to report Q1 earnings on April 25, appears undervalued after a 20.9% drop. Read why I am maintaining my Buy rating on HCA stock.

Best retirement portfolios blend income, reliability, and lasting power. Check out two core component picks of our diversified income-focused strategy.